logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Ascendis Pharma Announces 5-Year Phase 2 Data for TransCon PTH in HypoparathyroidismClinical Trial Updates

11 Jun 2026

Ascendis Pharma Announces 5-Year Phase 2 Data for TransCon PTH in Hypoparathyroidism

Ascendis Pharma A/S announced positive 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH (palopegteriparatide) in adults with...

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trialClinical Trial Updates

11 Jun 2026

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial

Takeda's investigational oral psoriasis drug, zasocitinib, significantly outperformed Bristol Myers Squibb’s Sotyktu in a Phase 3 study. Treatment with...

Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacyClinical Trial Updates

10 Jun 2026

Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy

Sanofi has decided to discontinue its Phase 3 MOBILIZE study for the investigational complement inhibitor riliprubart in chronic inflammatory demyelinating...

AstraZeneca's GLP-1 Pill Data Deemed 'Relatively Underwhelming' Against CompetitorsClinical Trial Updates

10 Jun 2026

AstraZeneca's GLP-1 Pill Data Deemed 'Relatively Underwhelming' Against Competitors

AstraZeneca's oral GLP-1 drug, elecoglipron, showed promising efficacy in mid-stage studies for weight control and type 2 diabetes, but its performance was...

Coya Therapeutics Begins Extension Phase of ALSTARS Trial for COYA 302Clinical Trial Updates

10 Jun 2026

Coya Therapeutics Begins Extension Phase of ALSTARS Trial for COYA 302

Coya Therapeutics has initiated the blinded extension phase of its Phase II ALSTARS trial for COYA 302, an investigational biologic therapy for amyotrophic...

Novo Nordisk Highlights Semaglutide Benefits and Pipeline at ADAClinical Trial Updates

09 Jun 2026

Novo Nordisk Highlights Semaglutide Benefits and Pipeline at ADA

Novo Nordisk presented over 40 abstracts and engaged with analysts at the American Diabetes Association (ADA) conference, impressing BMO Capital Markets with...

ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity marketClinical Trial Updates

09 Jun 2026

ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market

Pfizer presented positive Phase 2b data for berobenatide (from Metsera) at the 2026 American Diabetes Association meeting. The GLP-1 agonist demonstrated...

ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen assetClinical Trial Updates

09 Jun 2026

ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset

Eli Lilly's triple-G therapy, retatrutide, demonstrated impressive weight reduction in patients with obesity, solidifying the pharma's lead in the metabolic...

Roche Presents Positive Phase II Data for Acmopatide in Type 1 Diabetes at ADA 2026Clinical Trial Updates

09 Jun 2026

Roche Presents Positive Phase II Data for Acmopatide in Type 1 Diabetes at ADA 2026

Roche presented positive data from its randomized Phase II study of acmopatide in type 1 diabetes patients with overweight or obesity at the American Diabetes...

Eli Lilly Debuts Positive Retatrutide Data for Obesity ComorbiditiesClinical Trial Updates

09 Jun 2026

Eli Lilly Debuts Positive Retatrutide Data for Obesity Comorbidities

Eli Lilly presented new Phase III data for its 'triple G' agonist, retatrutide, at the American Diabetes Association (ADA) 2026 conference, demonstrating...

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reductionClinical Trial Updates

09 Jun 2026

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

Boehringer Ingelheim and Zealand Pharma's survodutide, a GLP-1/GIP candidate, presented Phase 3 data at the 2026 American Diabetes Association conference. In...

Zealand Pharma Announces Boehringer Ingelheim's Survodutide Phase III Trial Showed Targeted Fat Reduction in Obesity and MASLDClinical Trial Updates

07 Jun 2026

Zealand Pharma Announces Boehringer Ingelheim's Survodutide Phase III Trial Showed Targeted Fat Reduction in Obesity and MASLD

Zealand Pharma announced positive Phase III results for Boehringer Ingelheim's survodutide, a glucagon/GLP-1 dual agonist, from two global trials:...

Lilly’s Weight Loss Mastery Shows Benefits in Menopause, Sleep Apnea, MoreClinical Trial Updates

07 Jun 2026

Lilly’s Weight Loss Mastery Shows Benefits in Menopause, Sleep Apnea, More

Eli Lilly presented new data for its pipeline assets, retatrutide and Foundayo, at the American Diabetes Association Scientific Sessions. The triple agonist...

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyClinical Trial Updates

05 Jun 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion presented new clinical and translational data for its investigational oral menin inhibitor, icovamenib, at the American Diabetes Association...

ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonistClinical Trial Updates

05 Jun 2026

ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist

Roche and Zealand Pharma presented Phase 2 data for their amylin analog, petrelintide, at the 2026 American Diabetes Association conference. The ZUPREME-1...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesityClinical Trial Updates

05 Jun 2026

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity

Zealand Pharma announced additional data from its Phase 2 ZUPREME-1 trial of investigational petrelintide, an amylin analog, presented at the American Diabetes...

Lundbeck to Advance Migraine Drug Bocunebart After Positive Phase 2 DataClinical Trial Updates

05 Jun 2026

Lundbeck to Advance Migraine Drug Bocunebart After Positive Phase 2 Data

Lundbeck announced positive Phase 2 data for its investigational migraine prevention therapy, bocunebart, a PACAP inhibitor. The intravenous form of the drug...

Otsuka Energizes IgA Nephropathy Space with New Phase 3 Voyxact DataClinical Trial Updates

05 Jun 2026

Otsuka Energizes IgA Nephropathy Space with New Phase 3 Voyxact Data

Otsuka Pharmaceuticals' APRIL inhibitor, Voyxact, demonstrated stabilization of kidney function decline in interim Phase 3 VISIONARY trial data for IgA...

ASCO 2026: Darovasertib Raises the Bar in Metastatic Uveal MelanomaClinical Trial Updates

05 Jun 2026

ASCO 2026: Darovasertib Raises the Bar in Metastatic Uveal Melanoma

Primary results from the global, multi-centre, open-label Phase II/III OptimUM-02 clinical trial were presented at the American Society of Clinical Oncology...

ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drugClinical Trial Updates

05 Jun 2026

ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug

ADC Therapeutics' Zynlonta, combined with rituximab, faced significant challenges in the confirmatory Phase 3 LOTIS-5 study for diffuse large B cell lymphoma...

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” SegmentClinical Trial Updates

05 Jun 2026

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Moleculin Biotech announced that its CEO, Walter Klemp, highlighted the enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial. This trial...

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitClinical Trial Updates

05 Jun 2026

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

LeonaBio, Inc. announced that its Chief Medical Officer presented on brelgometon (ATH-1105) at the 5th Annual ALS Drug Development Summit. The presentation,...

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsClinical Trial Updates

05 Jun 2026

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

Novartis reported final 2.5-year Phase III ALIGN results for Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN). The study showed a clinically...

Peking University People’s Hospital Presents Phase I Results for Novel CD5 CAR-T TherapyClinical Trial Updates

05 Jun 2026

Peking University People’s Hospital Presents Phase I Results for Novel CD5 CAR-T Therapy

Peking University People’s Hospital presented Phase I results from its CONQUER trial at the ASCO Annual Meeting 2026, evaluating SL105, a novel nanobody-based...

Cardiff Oncology's Onvansertib Shows Promising Activity in RAS-Mutated mCRCClinical Trial Updates

05 Jun 2026

Cardiff Oncology's Onvansertib Shows Promising Activity in RAS-Mutated mCRC

Cardiff Oncology's Phase II CRDF-004 trial of onvansertib in RAS-mutated unresectable metastatic colorectal cancer (mCRC) demonstrated promising antitumor...

Gilead eyes PBC expansion for Livdelzi on positive one-year dataClinical Trial Updates

04 Jun 2026

Gilead eyes PBC expansion for Livdelzi on positive one-year data

Gilead Sciences announced positive 52-week data from its Phase III IDEAL study (NCT06060665) for Livdelzi (seladelpar) in primary biliary cholangitis (PBC)....

EMA, AMA and African Regulatory Authorities Join Forces on Ebola Outbreak ResponseClinical Trial Updates

04 Jun 2026

EMA, AMA and African Regulatory Authorities Join Forces on Ebola Outbreak Response

The European Medicines Agency (EMA), African Medicines Agency (AMA), and national regulatory authorities (NRAs) are collaborating to address the Ebola outbreak...

Inipharm Commences Dosing in INI-822 Trial for MASHClinical Trial Updates

04 Jun 2026

Inipharm Commences Dosing in INI-822 Trial for MASH

Inipharm has initiated dosing in a 12-week, placebo-controlled, double-blind proof-of-concept clinical study for its oral drug, INI-822, targeting metabolic...

Rezolute’s Stock Rises on Promising Interim Phase III Tumour HI DataClinical Trial Updates

04 Jun 2026

Rezolute’s Stock Rises on Promising Interim Phase III Tumour HI Data

Rezolute announced promising interim Phase III data for its drug ersodetug in patients with tumour hyperinsulinism (HI), causing its stock to rise over 10%. In...

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsClinical Trial Updates

04 Jun 2026

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

Novartis announced positive Phase III REPLENISH trial results for Cosentyx (secukinumab) in polymyalgia rheumatica (PMR), demonstrating statistically...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studyClinical Trial Updates

04 Jun 2026

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson announced positive Phase 2 JASMINE study results for nipocalimab in moderate-to-severe systemic lupus erythematosus (SLE). The study met its...

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in ObesityClinical Trial Updates

04 Jun 2026

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion has announced a research collaboration with the University of Leicester to evaluate its investigational menin inhibitor, icovamenib, in...

ASCO26: AstraZeneca’s AZD-3470 Demonstrates PRMT5 Inhibitor Safety for cHL PatientsClinical Trial Updates

02 Jun 2026

ASCO26: AstraZeneca’s AZD-3470 Demonstrates PRMT5 Inhibitor Safety for cHL Patients

AstraZeneca presented initial safety and efficacy data for AZD-3470, a PRMT5 inhibitor, in its Phase I PRIMAVERA study (NCT06137144) for relapsed/refractory...

Biohaven Looks to Obesity to Bounce Back from Clinical and Regulatory FailuresClinical Trial Updates

02 Jun 2026

Biohaven Looks to Obesity to Bounce Back from Clinical and Regulatory Failures

Biohaven is strategically pivoting its pipeline towards the lucrative obesity market with taldefgrobep alfa, a drug that previously failed a Phase 3 trial for...

ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancerClinical Trial Updates

02 Jun 2026

ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer

Merck and Chinese partner Kelun-Biotech presented positive Phase 3 interim overall survival (OS) data for their TROP2-directed antibody-drug conjugate,...

Labcorp announces partnership for colorectal cancer trialsClinical Trial Updates

02 Jun 2026

Labcorp announces partnership for colorectal cancer trials

Labcorp has partnered with the Alliance for Clinical Trials in Oncology for a new national, multi-centre study sponsored by the National Cancer Institute...

BioNTech and BMS Score in Bispecific Battle with Pumitamig DataClinical Trial Updates

02 Jun 2026

BioNTech and BMS Score in Bispecific Battle with Pumitamig Data

BioNTech and Bristol Myers Squibb presented positive Phase 2 data for their bispecific antibody pumitamig in combination with chemotherapy for previously...

Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in GastroparesisClinical Trial Updates

02 Jun 2026

Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis

Dr. Falk Pharma and Renexxion Ireland are advancing naronapride into late-stage development for the treatment of gastroparesis, following positive results from...

ASCO 2026: Monjuvi to rival Polivy in 1L DLBCL after strong Phase III resultsClinical Trial Updates

02 Jun 2026

ASCO 2026: Monjuvi to rival Polivy in 1L DLBCL after strong Phase III results

Incyte announced positive Phase III results for its CD19 monoclonal antibody, tafasitamab (Monjuvi/Minjuvi), in combination with lenalidomide and R-CHOP...

Moderna and MSD's Intismeran Reduces Melanoma Recurrence and Death Risk by 49%Clinical Trial Updates

02 Jun 2026

Moderna and MSD's Intismeran Reduces Melanoma Recurrence and Death Risk by 49%

Moderna and MSD presented five-year follow-up data from their Phase IIb KEYNOTE-942 study at ASCO 2026, demonstrating significant benefits for their...

← PrevPage 2 of 13Next →